Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials
Retrieved on:
Tuesday, June 1, 2021
Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.
Key Points:
- Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.
- In a preclinical experiment using a CPE (cytopathic effect assay), balixafortide demonstrated strong and robust activity against SARS-CoV-2 (COVID-19) infection at clinically relevant concentrations with no adverse cytotoxic effects.
- In an in vivo hamster animal model, balixafortide showed positive and statistically significant reduction of viral load of SARS COV-2.
- Balixafortide also reduced COVID19-relevant inflammation markers in the lung including ISG15 gene expression, a key player of respiratory failure in viral infections.